Advice

in the absence of a submission from the holder of the marketing authorisation:

eculizumab 300mg (Soliris®) is not recommended for use within NHSScotland.

Indication under review: Treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice622KB (PDF)

Download

Medicine details

Medicine name:
eculizumab (Soliris)
SMC ID:
SMC2456
Indication:

For treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.

Pharmaceutical company
Alexion Pharma UK Ltd
BNF chapter
Central nervous system
Submission type
Non submission
Status
Not recommended
Date advice published
17 January 2022